PROSPECT: A randomized phase III trial of neoadjuvant chemoradiation versus neoadjuvant FOLFOX chemotherapy with selective use of chemoradiation, followed by total mesorectal excision (TME) for treatment of locally advanced rectal cancer (LARC) (Alliance N1048).

Author:

Schrag Deborah1,Shi Qian2,Weiser Martin R.1,Gollub Marc J3,Saltz Leonard B.4,Musher Benjamin Leon5,Goldberg Joel6,Al Baghdadi Tareq7,Goodman Karyn A.5,McWilliams Robert R.8,Farma Jeffrey M.9,George Thomas J.10,Kennecke Hagen Fritz11,Venook Alan P.12,O'Reilly Eileen Mary12,Meyerhardt Jeffrey A.13,Dueck Amylou C.14,Basch Ethan15,Chang George J.16,Mamon Harvey J.6,

Affiliation:

1. Memorial Sloan Kettering Cancer Center, New York, NY

2. Alliance Statistics and Data Center, Mayo Clinic, Rochester, MN

3. Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY

4. Department of Colorectal Oncology, Memorial Sloan Kettering Cancer Center, New York, NY

5. SWOG, Portland, OR

6. Brigham and Women's Hospital, Boston, MA

7. IHA Hematology Oncology Consult, Ypsilanti, MI

8. Mayo Clinic, Rochester, MN

9. ECOG, Philadelphia, PA

10. NRG Oncology and The University of Florida Health Cancer Center, Gainesville, FL

11. Canadian Cancer Trials Group, Kingston, ON, Canada

12. Alliance for Clinical Trials in Oncology, Chicago, IL

13. Dana-Farber Cancer Institute, Boston, MA

14. Alliance Statistics and Data Management Center, Mayo Clinic, Rochester, MN

15. UNC Lineberger Comprehensive Cancer Center, Chapel Hill, NC

16. MD Anderson Cancer Center, Houston, TX

Abstract

LBA2 Background: Radiation with sensitizing fluoropyrimidine (5FUCRT) is a standard curative intent treatment for LARC. It improves disease-free survival (DFS) by decreasing pelvic recurrence but has short- and long-term toxicity. The PROSPECT trial compares FOLFOX chemotherapy with selective use of 5FUCRT (intervention) to 5FUCRT (control) for neoadjuvant treatment prior to TME for LARC. Methods: Eligible patients (pts) had cT2N+, cT3N-, cT3N+ rectal cancers deemed appropriate for neoadjuvant therapy prior to low anterior resection with TME. Pts with distal, T4 tumors, threatened radial margins or > 4 enlarged lymph nodes were ineligible. Pts were randomized 1:1 without blinding. Pts in the control group received 5FUCRT with 5040 cGy over 5.5 weeks with either capecitabine or 5FU. Pts in the intervention group had 6 cycles of mFOLFOX6 followed by restaging. If tumor regression was > 20%, then TME was performed without radiation; if < 20%, 5FUCRT was given before TME. DFS was the 1°outcome, defined as time from randomization to any recurrence or death, analyzed in the per-protocol population. One interim analysis was conducted with α spending = 0.001. Noninferiority (NI) of the intervention could be claimed if the upper limit of the 2-sided 90.2% confidence interval (CI) of the DFS hazard ratio did not exceed 1.29 (NI margin). Secondary endpoints included overall survival (OS), local recurrence free survival, R0 resection, pathologic complete response (CR), and toxicity. Results: From June 2012 to December 2018, 1194, pts were randomized and 1128 initiated protocol-assigned treatment. Median age was 57, 34.5% were women and 61.9% had clinically positive nodes. 53 of 585 pts in the intervention group (9%) received preop 5FUCRT. DFS was analyzed after 227 events and median follow-up of 58 months. Conclusions: FOLFOX chemotherapy with selective use of 5FUCRT is non-inferior to 5FUCRT for neoadjuvant treatment of LARC prior to low anterior resection with TME. Patients and physicians have alternative strategies for management of LARC. Clinical trial information: NCT01515787 . [Table: see text]

Funder

U.S. National Institutes of Health

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3